Skip to main content
Premium Trial:

Request an Annual Quote

BforCure Obtains CE Mark for Portable PCR Thermocycler to Detect SARS-CoV-2

NEW YORK ─ Paris-based point-of-care testing firm BforCure said on Monday that it has obtained CE marking for its Chronos Dx portable qPCR thermocycler, enabling its use for SARS-CoV-2 testing.

Chronos Dx uses a microfluidic thermal heating and cooling engine to rapidly cycle samples and enable multiplex qPCR testing in less than 15 minutes, BforCure said, adding it has placed its first portable thermocyclers for SARS-CoV-2 testing in France, including some at an undisclosed airport.

BforCure said it will retain Chronos Dx as an open platform to accommodate third party test kits for both in vitro diagnostic and research use, and it intends to develop additional tests in the near future.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.